We found that the PRS is associated with contralateral breast cancer risk in both BRCA1 and BRCA2 heterozygotes of European ancestry and that PRS can be used to refine estimates of contralateral breast cancer risks in these women. The gene discussed is BRCA1; the disease is breast cancer.